Designing monoclonal antibodies and related modalities such as ADCs and bispecifics with appropriate Fc function is critical to product safety and efficacy, but fiendishly hard. Outcomes are contextual, meaning that what works in one disease state/epitope setting may not hold in another, so the “rules” keep changing. And the factors driving Fc function are strongly interrelated, meaning that changes with one intent often have unexpected and undesirable consequences elsewhere. SeromYx offers the broadest and robust platform for Fc functional characterization.
Optimizing the Fab region in antibody panel construction is vital for drug development. However, Fab and Fc regions may not be functionally independent, each Fab can affect the Fc function differently. Early screening of intact molecules is crucial. Click the link below for your copy.
Recent Comments